Navigation Links
Amylin Pharmaceuticals to Present at the 2009 Deutsche Bank Biotech Boston Confab
Date:12/8/2009

SAN DIEGO, Dec. 8, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Deutsche Bank Biotech Boston Confab on Tuesday, December 15, 2009 at 1:35 p.m. ET / 10:35 a.m. PT in Boston. Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will provide a corporate overview.

The live presentation will be webcast, and a recording will be made available following the event. The webcast and recording will be accessible through Amylin's corporate Web site, located at www.amylin.com. To access the live webcast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information about Amylin Pharmaceuticals is available at www.amylin.com.

SOURCE Amylin Pharmaceuticals, Inc.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
2. Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid
3. Amylin Pharmaceuticals Reports Second Quarter Financial Results
4. Amylin Pharmaceuticals to Present Compelling Efficacy and Safety Data From Diabetes Programs at ADA 2009
5. Amylin Announces Preliminary Results of Annual Meeting of Stockholders
6. Amylin Advises All Shareholders to Vote Their Blue Proxy Card Today
7. Three Independent Proxy Advisory Firms Support Stockholder Nominees in Amylin Proxy Fight
8. Amylin Issues Statement Regarding Open Letter From Icahn
9. Icahn Issues Open Letter to Amylin Shareholders
10. Amylin Sends Letter to Shareholders
11. Amylin Pharmaceuticals Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2017)... ... June 24, 2017 , ... ... at the Sheraton Erie Bayfront and Erie Convention Center on June 8-10. ... exhibits, a student quiz bowl, award and scholarship presentations, and professional networking. ...
(Date:6/23/2017)... ... 23, 2017 , ... The Rhode Island Quality Institute (RIQI) ... and Dashboards, an innovative new service enabling healthcare providers to proactively coordinate care ... and Dashboards provide near real-time data about patients admitted to and/or discharged from ...
(Date:6/23/2017)... (PRWEB) , ... June 24, 2017 , ... Studies show ... significantly reduce the risk of visual loss in these patients. , But how often ... diet, or smoking cessation to patients at risk of or with early symptoms of ...
(Date:6/23/2017)... ... ... Everybody has their own personal preference when it comes to pornography. Some ... don't like it at all. FindaTopDoc took a look at what makes people attracted ... readers a taste of their deepest, darkest fantasies and has the ability to help ...
(Date:6/23/2017)... , ... June 23, 2017 , ... ... Cancer Conference from Sept. 18 to 20. , The two-day conference is focused ... with the goal of improving patients’ lives and eliminating racial breast cancer-related disparities. ...
Breaking Medicine News(10 mins):
(Date:6/13/2017)... June 13, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... announced that the U.S. Food and Drug Administration (FDA) has ... 2015 relating to its Zhejiang, China ... "The successful clearance of the Warning Letter related ... facility is a measure of the progress we have made ...
(Date:6/11/2017)... and Company (NYSE: LLY ) announced today ... an investigational treatment for the prevention of episodic and ... endpoints for galcanezumab compared to placebo at both studied ... REGAIN) will be presented today at the American Headache ... . "The detailed Phase 3 ...
(Date:6/9/2017)... PALO ALTO, Calif. , June 9, 2017 /PRNewswire/ ... medical device company focused on the design, manufacture, sale ... updated the market on the progress of its commercial ... AeroForm is now available in more than one hundred ... country. AeroForm offers a needle-free alternative ...
Breaking Medicine Technology: